Allander Biotechnologies, Inc.
Publicly observedAurora, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Aurora | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Allander Biotechnologies, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | J8KMX54WRJM9 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant16 Sept 2026Publicly observed
NIH SBIR/STTR award: cGMP manufacturing the clinical batch of oral gel drug for treating oral mucositis in cancer patients
USD 1,210,798.00 · National Institute of Dental and Craniofacial Research · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2025Publicly observed
NIH SBIR/STTR award: First-in-human clinical trial of proprietary oral gel to treat radiation-induced oral mucositis in cancer patients
USD 1,066,148.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2025Publicly observed
NIH SBIR/STTR award: First-in-human clinical trial of proprietary oral gel to treat radiation-induced oral mucositis in cancer patients
USD 1,233,852.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.